Aberrant glycosylation is a common feature of many
malignancies including
colorectal cancers (
CRCs). About 15% of CRC show the
microsatellite instability (MSI) phenotype that is associated with a high frequency of biallelic frameshift mutations in the
A10 coding mononucleotide microsatellite of the
transforming growth factor beta receptor 2 (
TGFBR2) gene. If and how impaired
TGFBR2 signaling in MSI CRC cells affects cell surface
glycan pattern is largely unexplored. Here, we used the TGFBR2-deficient MSI colon
carcinoma cell line HCT116 as a model system. Stable clones conferring
doxycycline (dox)-inducible expression of a single copy wildtype
TGFBR2 transgene were generated by
recombinase-mediated cassette exchange (RMCE). In two independent clones, dox-inducible expression of wildtype
TGFBR2 protein and reconstitution of its signaling function was shown. Metabolic labeling experiments using the tritiated
sialic acid precursor
N-acetyl-D-mannosamine (ManNAc) revealed a significant decline (∼30%) of its incorporation into newly synthesized
sialoglycoproteins in a TGFBR2-dependent manner. In particular, we detected a significant decrease of sialylated ß1-integrin upon reconstituted
TGFBR2 signaling which did not influence ß1-integrin
protein turnover. Notably,
TGFBR2 reconstitution did not affect the transcript levels of any of the known human
sialyltransferases when examined by real-time RT- PCR analysis. These results suggest that reconstituted
TGFBR2 signaling in an isogenic MSI cell line model system can modulate sialylation of
cell surface proteins like ß1-integrin. Moreover, our model system will be suitable to uncover the underlying molecular mechanisms of altered MSI
tumor glycobiology.